I think the preceding comment was operating on the presumption of linear returns from medical research. Since higher medical costs in the US goes directly towards medical companies, and indirectly to medical research after taxes and dividends and stockbuybacks...

Of course the biggest issue of all time is that germs are evolving to survive our antibacterial soap, we may need to develop a large variety of antibiotics.